Category - Developments

Developments

ImmunoPrecise Antibodies receives subcontract for rabbit monoclonal antibodies

ImmunoPrecise Antibodies (TSXV:IPA; OTC:IPATF) has received a five-year subcontract from Leidos Biomedical Research, which operates the Frederick National Laboratory for Cancer Research for the NCI, to discover and...

February 21, 2019

Developments

Clearlake Capital-backed symplr to acquire API Healthcare

symplr, a leading healthcare governance, risk and compliance (GRC) software-as-a-service (SaaS) platform, backed by Clearlake Capital Group, has agreed to acquire API Healthcare, a leading provider of healthcare human...

February 20, 2019

Developments

BioSig reports successful first-in-human use of PURE EP system

BioSig Technologies (NASDAQ:BSGM) reported that it successfully conducted first patient cases using its PURE EP system at the Texas Cardiac Arrhythmia Institute in Austin, Tex. PURE EP is an FDA-approved cardiac signal...

February 20, 2019

Developments

Corindus seeking premarket clearance for CorPath GRX in neurovascular procedures

Corindus Vascular Robotics (NYSE American:CVRS) is seeking premarket clearance from the FDA to expand the use of the CorPath GRX System, a second-generation robotic platform, in neurovascular procedures. In 2016...

February 14, 2019

Developments

IntelGenx adds Douglas Mental Health University Institute to Montelukast VersaFilm trial sites

IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to add Montreal’s Douglas Mental Health University Institute to its Montelukast VersaFilm Phase 2a clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD). World...

February 14, 2019

Developments

EyePoint Pharma secures debt facility of up to $60-million

EyePoint Pharmaceuticals (NASDAQ:EYPT) has secured a debt facility of up to $60-million from CR Group, a healthcare-focused investment firm, to retire existing debt and provide additional working capital to support...

February 13, 2019

Developments

Eyenovia expands MicroProst Phase 3 patient population for IOP lowering

Eyenovia (NASDAQ:EYEN) is expanding the patient population for its Phase 3 MicroProst program for the lowering of intraocular pressure (IOP). Following discussions with the FDA, the study population will include...

February 13, 2019

Developments

MIT-led research team unveil oral insulin capsule for Type 2 diabetes

Researchers from the Massachusetts Institute of Technology, Brigham and Women’s Hospital and Novo Nordisk have come up with an oral insulin pill that could replace injections for patients with Type 2 diabetes, according...

February 11, 2019

Developments

IntelGenx to receive Japanese patent for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQX:IGXT) received a Decision to Grant notice from the Japanese Patent Office (JPO) for the VersaFilm formulation used in its thin oral film RIZAPORT product for the treatment of acute migraines...

February 11, 2019

Developments

FDA accepts Eyenovia IND for Phase 3 MicroPine trial of myopia in children

The FDA accepted Eyenovia’s (NASDAQ:EYEN) IND to initiate the Phase 3 CHAPERONE registration trial of its MicroPine treatment to reduce the progression of myopia in children. The CHAPERONE study is a U.S.-based, multi...

February 6, 2019

Category - Developments

Subscribe